Clinical trialNCT04364737CompletedPhase 2Interventional

CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients

SponsorNYU Langone HealthEnrollment941COVID-19CoronavirusCoronavirus Infection

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Mila B Ortigoza, MD, PhD
NYU Langone Health
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Yale University School of Medicine
New Haven, Connecticut, United States
University of Miami Hospital and Clinics
Miami, Florida, United States
Nyu Langone Health
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
University of Texas Rio Grande Valley
Edinburg, Texas, United States
the University of Texas Health Science Center
Houston, Texas, United States
the University of Texas Health Science Center
Tyler, Texas, United States
Aurora St. Luke'S Medical Center
Milwaukee, Wisconsin, United States
Medical College of Wisconsin / Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Convalescent Plasma

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Apr 2020
Primary completion: 29 Mar 2021
Completion: 12 Dec 2022
Last update posted: 26 Jan 2023
Registered enrollment: 941
Registry id: NCT04364737

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.